Compare EML & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EML | ONCY |
|---|---|---|
| Founded | 1858 | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.1M | 107.3M |
| IPO Year | 1995 | 2002 |
| Metric | EML | ONCY |
|---|---|---|
| Price | $25.32 | $0.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.33 |
| AVG Volume (30 Days) | 59.6K | ★ 1.1M |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.98% | N/A |
| EPS Growth | ★ 185.40 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $248,970,345.00 | N/A |
| Revenue This Year | $19.05 | N/A |
| Revenue Next Year | N/A | $2,505.00 |
| P/E Ratio | $235.55 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.61 | $0.77 |
| 52 Week High | $29.91 | $1.51 |
| Indicator | EML | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 54.61 | 48.52 |
| Support Level | $18.34 | $0.79 |
| Resistance Level | $29.91 | $1.06 |
| Average True Range (ATR) | 1.39 | 0.07 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 37.81 | 39.65 |
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to the industrial market. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It has one reportable segment: Engineered Solutions, which provides engineered solutions mainly for the commercial transportation and logistics markets. This segment offers a diverse product line of custom and standard vehicular and industrial hardware, including turnkey returnable packaging solutions, blow molds, compression latches, draw latches, hinges, camlocksaccess, mirrors, and mirror-cameras, among other products. Geographically, the group derives maximum revenue from the United States.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.